Lilliana Vazquez Rivera
Infectious Disease · North Miami Beach, FLNPI 1205097953
Payments from drug & device makers
Across 384 payments — averaging $94.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$13K
- Gilead$11K
- Merck$10K
- Johnson & Johnson$724
- Janssen Products, LP$700
- Theratechnologies Inc.$213
- plus $653 from 10 others
What the payments were for
- Consulting fees$12,51534%
- Speaking & faculty fees$14,20039%
- Travel & lodging$1,7255%
- Food & beverage$7,87222%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 160 | $13,065 |
| Gilead | 106 | $10,838 |
| Merck | 39 | $10,223 |
| Johnson & Johnson(2 entities) | 47 | $724 |
| Janssen Products, LP | 3 | $700 |
| Theratechnologies Inc. | 7 | $213 |
| Lilly USA, LLC | 6 | $199 |
| AbbVie(2 entities) | 2 | $151 |
| EMD Serono, Inc. | 3 | $77 |
| Exact Sciences | 3 | $65 |
| Pfizer | 2 | $40 |
| Hologic Sales And Service, LLC | 1 | $29 |
| Dynavax Technologies Corporation | 2 | $24 |
| AstraZeneca | 1 | $24 |
| Napo Pharmaceuticals Inc | 1 | $24 |
| Amgen | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,416 in reported general payments places this provider in the 85th percentile of 669 infectious disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 47 | $188,313 |
| JulucaDolutegravir/Rilpivirine | 27 | $93,497 |
| TivicayDolutegravir Sodium | 35 | $79,995 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 15 | $78,805 |
| PrezcobixDarunavir/Cobicistat | 24 | $60,509 |
| Ezetimibe | 14 | $352 |
| Rosuvastatin Calcium | 13 | $272 |
| Atorvastatin Calcium | 12 | $130 |
| Metformin Hcl | 13 | $32 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $10,838 | $188,31347 claims |
| Viiv Healthcare CompanyJuluca, Tivicay | $13,065 | $173,49262 claims |
| Janssen Products, LPSymtuza | $700 | $78,80515 claims |
| Johnson & JohnsonPrezcobix | $724 | $60,50924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 669 infectious disease providers in Florida.
Other infectious disease in North Miami Beach
- Moti RamgopalFort Pierce$13.5M
- Larry BushAtlantis$9.3M
- Olayemi OsiyemiWest Palm Beach$8.8M
- Charlotte-Paige RolleOrlando$6M
- Edwin DejesusOrlando$5.9M
- Dushyantha JayaweeraMiami$5.1M
- Federico HinestrosaOrlando$5.1M
- Godson OguchiOrange City$5M
- Ammara MushtaqGainesville$2.7M
- Efrain GarciaMiami$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.